This company is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Humanigen Beheer
Beheer criteriumcontroles 2/4
We currently do not have sufficient information about the CEO.
Belangrijke informatie
Cameron Durrant
Algemeen directeur
n/a
Totale compensatie
Percentage CEO-salaris | n/a |
Dienstverband CEO | 8.3yrs |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | geen gegevens |
Gemiddelde ambtstermijn bestuur | 7.5yrs |
Recente managementupdates
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Mar 31 2023 | n/a | n/a | -US$54m |
Dec 31 2022 | US$1m | US$640k | -US$71m |
Sep 30 2022 | n/a | n/a | -US$109m |
Jun 30 2022 | n/a | n/a | -US$152m |
Mar 31 2022 | n/a | n/a | -US$192m |
Dec 31 2021 | US$10m | US$640k | -US$237m |
Sep 30 2021 | n/a | n/a | -US$235m |
Jun 30 2021 | n/a | n/a | -US$199m |
Mar 31 2021 | n/a | n/a | -US$153m |
Dec 31 2020 | US$2m | US$600k | -US$90m |
Sep 30 2020 | n/a | n/a | -US$59m |
Jun 30 2020 | n/a | n/a | -US$31m |
Mar 31 2020 | n/a | n/a | -US$10m |
Dec 31 2019 | US$785k | US$600k | -US$10m |
Sep 30 2019 | n/a | n/a | -US$10m |
Jun 30 2019 | n/a | n/a | -US$10m |
Mar 31 2019 | n/a | n/a | -US$9m |
Dec 31 2018 | US$4m | US$600k | -US$12m |
Sep 30 2018 | n/a | n/a | -US$13m |
Jun 30 2018 | n/a | n/a | -US$18m |
Mar 31 2018 | n/a | n/a | -US$22m |
Dec 31 2017 | US$790k | US$600k | -US$22m |
Compensatie versus markt: Insufficient data to establish whether Cameron's total compensation is reasonable compared to companies of similar size in the US market.
Compensatie versus inkomsten: Cameron's compensation has been consistent with company performance over the past year.
CEO
Cameron Durrant (64 yo)
8.3yrs
Tenure
US$1,099,058
Compensatie
Dr. Cameron Durrant, MD, MBA, DRCOG, DIPCH, MRCGP, FLSW, has been Chairman of Humanigen, Inc. since January 2016. Dr. Durrant has been Chief Executive Officer at Humanigen, Inc. since March 2016 and has be...
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chairman | 8.5yrs | US$1.10m | geen gegevens | |
Chief Scientific Officer & Director | 3.4yrs | US$661.96k | 0% $ 0 | |
Independent Director | 6.4yrs | US$81.20k | 0.071% $ 0.08 | |
Independent Director | 8.5yrs | US$61.60k | 0.075% $ 0.09 |
7.5yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: HGEN.Q's board of directors are considered experienced (7.5 years average tenure).